title: Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate.
abstract: Phenylbutyrate (PB), a novel lead compound for prostate cancer therapy, has molecular activities distinct from its metabolite, phenylacetate (PA). Both PB and PA promote differentiation in human prostate cancer cell lines, yet little data exist comparing the cytotoxic effects of each drug. We found that PB is more potent than PA in vitro; PB is 1.5-2.5 times more active at inhibiting growth and inducing programmed cell death than PA at clinically achievable doses against each human prostate cancer line studied. PB is equipotent to sodium butyrate, which induces apoptosis and differentiation through multiple mechanisms. Exposure of prostate cancer cell lines to PB reduces their DNA synthesis, leads to fragmentation of genomic DNA, and causes 50-60% of cells to undergo apoptosis. These PB-induced effects are 2-10 times greater than those of the control or PA. The stereotypical changes of apoptosis can be seen with sodium butyrate at similar concentrations, but not with PA. Prostate cancer cell lines overexpressing P-glycoprotein or possessing heterogeneous molecular alterations, including p53 mutations, are also sensitive to the effects of PB. In vivo, Copenhagen rats treated with oral PB had delayed growth of the androgen refractory Dunning R-3327 MAT-LyLu prostate cancer subline by 30-45% in a dose-dependent manner. These results demonstrate that PB induces cytotoxicity via apoptosis in human prostate cancer, in addition to its differentiating properties.
authors.affiliation: The Johns Hopkins Oncology Center and The Brady Urological Institute, Baltimore, Maryland 21205, USA. carducci@welchlink.welch.jhu.edu
authors.forename: M A
authors.initials: MA
authors.lastname: Carducci
authors.forename: J B
authors.initials: JB
authors.lastname: Nelson
authors.forename: K M
authors.initials: KM
authors.lastname: Chan-Tack
authors.forename: S R
authors.initials: SR
authors.lastname: Ayyagari
authors.forename: W H
authors.initials: WH
authors.lastname: Sweatt
authors.forename: P A
authors.initials: PA
authors.lastname: Campbell
authors.forename: W G
authors.initials: WG
authors.lastname: Nelson
authors.forename: J W
authors.initials: JW
authors.lastname: Simons
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D020148:Butyric Acid / Q000494:pharmacology; D004247:DNA / Q000096:biosynthesis; D006801:Humans; D008297:Male; D010648:Phenylacetates / Q000494:pharmacology*; D010654:Phenylbutyrates / Q000494:pharmacology*; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D051381:Rats; D014407:Tumor Cells, Cultured
chemical_list: D000970:Antineoplastic Agents; D010648:Phenylacetates; D010654:Phenylbutyrates; D020148:Butyric Acid; D004247:DNA; C025136:phenylacetic acid